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Cardiac resynchronization therapy (CRT) is an established
treatment for symptomatic patients with heart failure (HF), a
prolonged QRS duration, and reduced ejection fraction (EF).
The latest 2013 European Society of Cardiology Guide-
lines on cardiac pacing and cardiac resynchronization therapy
(1) support recommendations for the use of CRT in patients
with QRS duration of120 ms and EF35%, to reduce the
risk of HF hospital stay and premature death. In the
Guidelines were considered patients in sinus rhythm and
patients with permanent or long-standing persistent atrial
ﬁbrillation (AF) with hemodynamic indication for CRT or
with a fast ventricular rate justifying a strong rate control
strategy with an atrioventricular (AV) junction ablation.See page 1190The MUSTIC (MUltisite STimulation in cardiomyopa-
thy) trial (2) included 59 patients with HF and reduced EF
with persistent/permanent AF, slow ventricular rate, per-
manent pacing, and a paced QRS duration >200 ms. There
was a high drop-out (42%), and no difference in primary
endpoint of 6-min walking distance. The per-protocol
analysis including only patients with a biventricular pacing
rate >85% did show a slight but signiﬁcant improve-
ment in functional status at 6-month and 1-year follow-up.
The RAFT (Resynchronization/Deﬁbrillation for Ambu-
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disclose.permanent AF or atrial ﬂutter either with controlled ven-
tricular rate or with planned AV junction ablation. The
analysis showed a signiﬁcant interaction between baseline
rhythm and treatment effect.
In theAPAF(Ablate andPace inAtrial Fibrillation) trial (4),
patients were treated with CRT and AV junction ablation; in
the subgroups of patients with low EF, New York Heart As-
sociation functional class III, and QRS 120 ms, CRT
signiﬁcantly reduced the primary endpoint, including death
from HF, hospital stays, or worsening of HF. The same ﬁnd-
ings were observed in the left ventricular-based cardiac stimu-
lation PAVE (Post AV Nodal Ablation Evaluation) trial (5).
Wilton et al. (6), in a meta-analysis from 33 observational
studies with 22.5% AF patients, compared outcomes in
patients with and without AF receiving CRT. They reported
in patients with AF an increased risk of nonresponse to
CRT (34.5 vs. 26.7%; p ¼ 0.01) and all-cause mortality
(10.8 vs. 7.1%/year; p ¼ 0.001). The AV junction ablation
seemed favorable with a lower risk of clinical nonresponse
(risk ratio: 0.40; p < 0.001) and a reduced risk of death.
In addition, Santini et al. (7) evaluated the correlation
between atrial tachycardia (AT) or AF and clinical out-
comes, such as survival or HF hospital stays, in a large
population of patients with CRT implantable cardioverter-
deﬁbrillators (CRT-D), according to 5 AT/AF burdens,
whose lengths were >10 min, >6 h, >24 h, >7 days, and
>6 months. Patients with persistent or permanent AT/AF
had higher incidences of the composite endpoint or HF
hospital stay when compared with patients in sinus rhythm.
It has been shown that the greatest improvement and
reduction in mortality occur with a biventricular pacing
>98% (8). Therefore, failure of biventricular capture might
explain the lack of beneﬁt of CRT in patients with persis-
tent/permanent AF (9).
In this issue of the Journal, Ruwald et al. (10) assessed the
effect of intermittent atrial tachyarrhythmias (IAT) before
and during CRT-D in 1,241 patients of the MADIT-CRT
trial (Multicenter Automatic Deﬁbrillator Implantation Trial-
Cardiac Resynchronization Therapy) (11). The study showed
that the percentage of biventricular pacing was similar in both
group. The cumulative endpoint of HF, hospital stay, and
death was signiﬁcantly reduced in patients treated with CRT-
D with and without a history of IAT, compared with ICD-
only therapy. Unfortunately, the investigators were unable to
detect atrial arrhythmias with ventricular rate<180 beats/min
and provided no data on arrhythmias burden.
With the current level of knowledge, how should clini-
cians treat patients with AT/AF and HF?
In our opinion, all patients who meet the recommended
criteria for CRT, despite their atrial arrhythmias burden,
should receive this therapy. Gasparini et al. (12) demon-
strated that patients with permanent AF, treated with CRT,
and candidates for AV junction ablation gain the same
beneﬁt as patients in sinus rhythm. The potential beneﬁts
must be balanced against the risks associated with creating
pacemaker dependency. Thus, AV junction ablation can be
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and device functioning assessment.
Moreover, the EuroHeart Failure survey reported that
up to 45% of patients with HF and sinus rhythm also pre-
sented with intermittent or permanent AF (13). Ruwald
has shown that patients with or without a history of IAT
had signiﬁcant reduction in left atrial volume within 1 year
of follow-up. Favorable reverse remodeling of the left atrium
with CRT was associated with a signiﬁcant reduction in
risk of subsequent atrial tachyarrhythmias (14). A particular
aspect of AF patients is that AF rhythm with a fast
ventricular rate and irregularity might interfere with
adequate biventricular pacing delivery (1). Device di-
agnostics allow a continuous monitoring of cardiac ar-
rhythmias, evaluation of AT/AF occurrence and duration,
and information about lead, and device function. These
web-based care alerts might determine clinical re-evaluation
of current treatment to optimize rhythm or rate control.
Moreover, the newest devices give us information also on
reduced physical activity or volume overload. All these data
are helpful to detect patients with high risk of worsening
clinical condition, to improve medical treatment and CRT
device programming, and avoid further hospital stay and
progression of HF.
In conclusion, the beneﬁcial effects of CRT in patients
with atrial tachyarrhythmias are related to the percentage
of biventricular pacing and to the burden of AT/AF. To
reduce interference on biventricular capture, we can optimize
medical therapy and, in case of AF with inadequate heart
rate control, perform AV junction ablation.
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